Should I buy Bayer stock in 2025? Expert Advice for Ireland

What is Bayer?

How much is the Bayer stock?

The price of Bayer stock is rising this week. As of now, Bayer trades at €24.82, reflecting a 0.36% gain in the past 24 hours and a 1.5% increase over the last week. The company’s market capitalisation stands at €24.36 billion, with an average three-month trading volume of 4.48 million shares.

Currently, the P/E ratio is low at 5.58, the dividend yield is modest at 0.45%, and beta data is not available.

With recent price momentum and a strong technical outlook, Bayer’s shares may offer opportunities for Irish investors seeking value in a recovering European healthcare leader.

Our full analysis on Bayer stock

Having thoroughly examined Bayer AG’s latest financial performance, scrutinised price developments over the past three years, and synthesised proprietary algorithmic insights drawn from financial indicators, technical momentum, market data, and a comparative peer review, a compelling picture has emerged. This analysis seeks to decode Bayer’s current market position and illuminate the strategic rationale behind its growing investor appeal. So, why might Bayer stock once again become a strategic entry point into the healthcare and agritech sector in 2025?

Recent Performance and Market Context

Over the last six months, Bayer AG shares have demonstrated remarkable resilience and positive momentum, posting a robust +27.53% rise to €24.82 as of May 30, 2025—an outperformance compared to broader market indices and many sector peers. While the one-year trajectory reflects a decline of 12.45%, this moderation must be contextualised within a year marked by cyclical headwinds and sector-specific volatility, notably in agriculture.

Recent weeks have been particularly encouraging:

• FDA Priority Review (May 2025): The acceptance of Bayer's sevabertinib NDA under priority review signals regulatory confidence and a potential blockbuster addition to the pharmaceutical pipeline.
• Affirmed 2025 Guidance: Management’s reaffirmation of FY25 targets following a solid Q1 print instils clarity and credibility, restoring market confidence.
• Cost-Savings Acceleration: The roll-out of an €800 million cost-optimisation programme for 2025 underscores a disciplined operational focus, supportive of future margin expansion.

Macro and sectoral tailwinds—such as the ongoing global demand for healthcare innovation, coupled with the agricultural sector’s increasing digitisation and sustainability focus—provide a constructive backdrop, well-aligned with Bayer’s twin strengths in pharmaceuticals and crop science. The confluence of improving sentiment, analyst upgrades (Barclays lifting its price target to €25), and upward volume trends all reinforce the view that a new growth phase may be emerging.

Technical Analysis

Bayer’s technical chart presents multiple indicators of a sustained bullish turnaround:

• Relative Strength Index (RSI, 14-day): Sitting at 61.21, the RSI points to healthy yet not overbought conditions—indicating potential for further upside.
• MACD: While registering a slight sell signal (+0.58), this is minor compared to the overwhelmingly bullish consensus among other indicators.
• Moving Averages: The short-, medium-, and long-term moving averages are all positioned beneath the current price (€24.82 vs. 20-day MA at €23.80, 50-day at €22.68, 100-day at €22.13, and 200-day at €23.27), each flashing strong buy signals and providing robust foundational support.
• Support & Resistance: Clear technical support in the €23.52–€24.08 and €22.75–€23.04 ranges, while resistance at €24.86–€24.93 and €25.93 suggests manageable ceilings to further upside.
• Technical Momentum: An overall 'strong buy' technical rating, with 15 bullish and just 2 bearish signals, corroborates the broader pattern of accumulation and steady momentum.

Short- to medium-term price structure is thus defined by constructive technicals, offering an ideal window for potential entry, especially as the stock consolidates above key moving averages with volume alignment.

Fundamental Analysis

From a fundamental standpoint, Bayer’s valuation currently stands out:

• Revenue & Earnings: Despite a marginal year-on-year decline (Q1 sales at €13.738bn vs. €13.765bn in Q1 2024), performance in Q1 2025 notably exceeded market expectations, especially in the pharmaceuticals division. EBITDA before special items remains robust.
• Valuation Metrics: A price-to-earnings (P/E) ratio of just 5.58 and a price-to-sales of 0.52 highlight how the stock is trading at a significant discount to both its historical median and key rivals—suggesting a 'value' profile with embedded growth optionality.
• Strategic Expansion: Persistently high R&D investment supports innovation, powering a diversified growth trajectory across healthcare, consumer health, and modern crop science.
• Brand and Market Strength: Bayer’s reputation is underpinned by its global reach (over 90,000 employees), deep scientific expertise, and a balanced business portfolio which mitigates cyclical risks.

Structurally, Bayer’s capacity for resilient profitability, innovation leadership, and brand equity places it in a unique position as both a defensive anchor and a platform for growth.

Volume and Liquidity

Sustained volume levels—averaging 4.48 million shares traded daily—signal robust participation from global institutional and retail investors, reflecting a high degree of market confidence and ease of entry or exit. The liquidity profile supports dynamic valuation discovery and reduces execution risk for investors, while a free float structure (982 million shares outstanding) provides flexibility for sophisticated allocations and portfolio adjustments.

Notably, higher volumes during recent upswings confirm genuine accumulation, rather than short-lived speculative activity. This volume trend, against the backdrop of the stock’s consolidation phase, offers another argument for renewed interest at current levels.

Catalysts and Positive Outlook

Several forward-looking catalysts distinguish Bayer as one of the sector’s more compelling opportunities for 2025 and beyond:

• Pharmaceutical Pipeline Maturation: The FDA’s priority review of sevabertinib, along with a diversified late-stage pipeline, positions Bayer favourably for near-term clinical and commercial breakthroughs.
• Cost Optimisation Programme: Delivery of €800 million in 2025 cost savings is likely to drive further earnings leverage and margin improvement.
• Digital and Agricultural Innovation: Bayer’s leading investments in crop science and digital agriculture underscore its position at the intersection of global food security and sustainable environmental practices.
• ESG Initiatives: The group is proactively responding to rising regulatory and consumer demands for sustainable solutions, which enhances its reputational advantage and supports long-term relevance.
• External Tailwinds: Macro trends for healthcare (aging populations, rising chronic disease prevalence) and agri-science (food supply chain resilience, climate adaptation) continue to present an expanding addressable market.

Collectively, these factors set the stage for ongoing upgrades to consensus targets (the average analyst price target sits at €27.71, a projected 12–15% upside), with further catalysts potentially providing additional re-rating opportunities.

Investment Strategies

Bayer’s technical and fundamental dynamics make it relevant for a variety of investor timeframes:

• Short-Term: A potential window exists near current support levels (€23.52–€24.08), where technical momentum and forthcoming catalysts (e.g., FDA decisions) could spark breakout moves.
• Medium-Term: The unfolding of cost savings, recovery in the agricultural cycle, and imminent pharmaceutical milestones offer fertile ground for value realisation over the next 6–12 months.
• Long-Term: Structural strengths—such as robust R&D, a diversified portfolio, and global brand power—position Bayer as a staple for investors seeking both defensive characteristics and scalable growth over multi-year horizons.

Ideal positioning may be achieved at the lower end of current trading bands or ahead of major catalyst releases, allowing investors to harness both technical recovery and fundamental re-rating potential.

Is it the Right Time to Buy Bayer?

In sum, Bayer AG appears to blend undervalued fundamentals with strong technical momentum and clearly defined catalysts, presenting a particularly attractive risk/reward trade-off at current levels. The group combines an improving earnings outlook, affirmed guidance, and robust cost-control initiatives with high-impact pipeline events—especially as the stock trades well below both long-term averages and consensus price targets.

With a deep innovation engine, compelling valuation metrics, and renewed investor confidence, Bayer seems to represent an excellent opportunity for those seeking exposure to the transformative trends shaping healthcare and agriculture. As 2025 unfolds, these strengths position Bayer not only for near-term recovery but also for sustainable, long-term value creation—a scenario that justifies serious consideration for fresh capital allocation at this juncture.

For those with a keen eye on value, innovation, and resilient growth, Bayer’s combination of momentum and fundamentals may indeed signal the emergence of a new bullish phase—offering an unmistakable opportunity for those seeking to participate in the next chapter of this iconic European sector leader.

How to buy Bayer stock in Ireland?

Buying Bayer stock online is a straightforward and secure process for Irish investors when you use a regulated broker. You can own Bayer shares in two main ways: either by purchasing the stock outright (spot buying), or by trading Contracts for Difference (CFDs), which let you speculate on the share price without owning the asset. Both methods are accessible from Ireland, with quick account setup and protection under EU financial regulations. Below, you’ll find guidance on the differences between these investment methods, and a broker comparison to help you choose the best platform for your needs.

Spot Buying (Cash Purchase)

When you buy Bayer shares for cash, you become a direct shareholder in the company: your name (or your broker’s nominee) is recorded on the shareholder register, giving you the right to any dividends and to vote at AGMs. Most regulated brokers charge a fixed commission per trade—typically ranging from €4 to €10 for each online order in Ireland.

Example

Suppose Bayer shares trade at €24.82 per share, and you have €1,000 to invest. Accounting for a brokerage fee of around €5, you could purchase approximately 40 shares (€1,000 – €5 = €995; €995 ÷ €24.82 ≈ 40 shares).

• ✔️ Gain scenario: If the share price goes up by 10% (to €27.30), your holding is now worth about €1,100.
• Result: That’s a gross gain of €100, which represents a 10% increase on your original investment (excluding taxes and smaller variable fees).

Trading via CFD

Trading Bayer shares with CFDs (Contracts for Difference) means you do not own the underlying shares but instead speculate on price movements—up or down. CFDs allow you to use leverage, meaning you can gain greater market exposure with a smaller upfront deposit. Brokers charge a “spread” (the difference between buy and sell price) and may apply overnight financing fees if you hold your position several days.

Example

Imagine you wish to invest €1,000 in Bayer via CFDs and use 5x leverage. Your exposure to the market is now €5,000.

• ✔️ Gain scenario: If Bayer’s share price rises by 8%, your position gains 8% × 5 = 40%.
• Result: That’s a €400 gain on your €1,000 investment (not including spreads or overnight fees). Please note, losses are also magnified—and you could lose more than your deposit if the price moves against you.

Final Advice

Before you invest in Bayer or any international shares, it’s essential to compare brokers’ fees, currency conversion costs, available platforms, and investor protections. Each method—spot buying or CFD trading—carries distinct opportunities and risks, so your choice should reflect your objectives and experience. For a detailed side-by-side comparison of leading brokers suitable for investors in Ireland, please refer to the broker comparison further down the page.

Our 7 tips for buying Bayer stock

The latest news about Bayer

Bayer received FDA priority review for its new oncology drug sevabertinib on May 28, 2025, signaling US regulatory momentum. This development reinforces Bayer’s pharmaceutical expansion strategy and points toward potential future revenue enhancement from new product approvals. The FDA priority review increases visibility among institutional investors and demonstrates the company’s focus on innovative treatments, which is particularly well regarded by Irish and other European healthcare investors who prioritize exposure to growth areas in global pharma markets.

Bayer confirmed its 2025 outlook following a stronger-than-expected Q1 2025, led by robust Pharmaceuticals performance. The group’s Q1 sales reached €13.738 billion, with results slightly exceeding market expectations, mainly in the pharmaceutical segment. For Irish investors and analysts, this confirmation provides assurance of operational stability and clear management clarity, supporting confidence in the stock’s fundamentals during a period of industry realignment across European healthcare names.

The technical outlook for Bayer is strongly bullish, with all key moving averages flashing a buy signal and overall consensus ranked as “Strong Buy.” Major technical indicators, including the 20-, 50-, 100-, and 200-day moving averages, now support a continuation of the recent rally, with Bayer up 1.5% over the past week and 27.5% over six months. For Ireland-based professional investors, this technical strength—contrasted with a low price/earnings multiple and stable support levels—highlights an attractive risk/reward profile, especially for portfolios seeking defensive European exposure with momentum.

Barclays recently upgraded Bayer’s price target to €25, contributing to a consensus target of €27.71 (over 12% upside). The analyst community, now consolidated around an upside scenario with three “Buy” ratings and a majority “Hold,” underscores the stock’s compelling valuation story. For Irish institutional holders, this broadly positive analyst sentiment, combined with upward price target revisions, signals increasing confidence from international market participants, enhancing Bayer’s appeal as a diversified healthcare and agritech play.

Bayer’s ongoing €800 million 2025 cost-savings program and global focus on R&D innovation provide medium-term strategic tailwinds. The execution of this cost-optimization initiative is expected to bolster operating margins and underpin earnings resilience, especially in an environment of European healthcare inflation and sector consolidation. The company’s commitment to innovation and sustainable agriculture is aligned with Ireland’s strategic priorities in life sciences and agri-food sectors, reinforcing the relevance and attractiveness of Bayer for locally focused investment portfolios.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.